Carrick Therapeutics has licensed an ovarian cancer drug from BTG. The British biotech is working to get the former Onyx Therapeutics drug into pivotal trials on the strength of phase 1 data.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,